| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2883057 | The Annals of Thoracic Surgery | 2006 | 10 Pages |
Abstract
A dose-related increased incidence of brain metastases after adjuvant therapy for esophageal cancer cannot be explained by increased longevity. Adjuvant therapy itself, not just advanced disease, appears to create conditions conducive to developing these rapidly fatal metastases.
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Thomas W. MD, Deepak MD, Lisa A. MS, David J. MD, Michael A. MD, PhD, David P. MD, Sudish C. MD, PhD, Eugene H. MD,